Aclarion, Inc. (NASDAQ:ACON) Short Interest Update

Aclarion, Inc. (NASDAQ:ACON) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 42,256 shares, an increase of 142.6% from the November 30th total of 17,416 shares. Based on an average daily volume of 114,351 shares, the short-interest ratio is currently 0.4 days. Approximately 6.3% of the shares of the company are short sold. Approximately 6.3% of the shares of the company are short sold. Based on an average daily volume of 114,351 shares, the short-interest ratio is currently 0.4 days.

Aclarion Price Performance

Aclarion stock opened at $5.89 on Friday. The business has a 50 day simple moving average of $6.74 and a 200 day simple moving average of $7.25. The company has a market capitalization of $3.95 million, a PE ratio of -0.39 and a beta of 1.43. Aclarion has a one year low of $5.55 and a one year high of $3,499.51.

Aclarion (NASDAQ:ACON) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($2.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.64) by ($0.29). Aclarion had a negative net margin of 10,908.50% and a negative return on equity of 67.53%. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. Equities analysts anticipate that Aclarion will post -263.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aclarion in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Aclarion currently has an average rating of “Sell”.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.